The Taiwan Precision Medicine Initiative (TPMI) is a partnership between Academia Sinica and top medical centers in Taiwan to bring genetic information into clinical practice. By profiling 1 million participants with a set of genetic markers designed for Taiwan, we aim to optimize patient care by preventing dangerous drug side-effects, early cancer screening for those at high risk, and encouraging life-style changes for those at risk for other serious diseases.

Cumulatively, our center has collected the DNA of 46,000 individuals and analyzed the genetic results of 45,000 individuals.